{"id":57943,"date":"2026-02-25T16:36:19","date_gmt":"2026-02-25T08:36:19","guid":{"rendered":"https:\/\/flcube.com\/?p=57943"},"modified":"2026-02-25T16:36:20","modified_gmt":"2026-02-25T08:36:20","slug":"dupixent-wins-fda-approval-for-allergic-fungal-rhinosinusitis-first-targeted-therapy-for-afrs-expands-dupilumab-label","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57943","title":{"rendered":"Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis \u2013 First Targeted Therapy for AFRS Expands Dupilumab Label"},"content":{"rendered":"\n

Sanofi (NASDAQ:\u202fSNY<\/a>)<\/strong> and Regeneron (NASDAQ:\u202fREGN<\/a>)<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved Dupixent (dupilumab)<\/strong> for the treatment of adult and pediatric patients aged 6 years and older<\/strong> with allergic fungal rhinosinusitis (AFRS)<\/strong> who have a history of sino\u2011nasal surgery. The approval marks the first targeted therapy<\/strong> for AFRS, a chronic type\u202f2 inflammatory disease driven by allergic hypersensitivity to fungi.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Companies<\/strong><\/td>Sanofi (NASDAQ:\u202fSNY) + Regeneron (NASDAQ:\u202fREGN)<\/td><\/tr>
Product<\/strong><\/td>Dupixent (dupilumab)<\/td><\/tr>
Regulatory Body<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
New Indication<\/strong><\/td>Allergic fungal rhinosinusitis (AFRS)<\/td><\/tr>
Patient Population<\/strong><\/td>Adults and pediatrics \u2265\u202f6 years with history of sino\u2011nasal surgery<\/td><\/tr>
Clinical Study<\/strong><\/td>LIBERTY\u2011AFRS\u2011AIMS Phase\u202f3 (NCT04684524)<\/td><\/tr>
Significance<\/strong><\/td>First FDA\u2011approved targeted therapy for AFRS<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context \u2013 AFRS<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Disease Type<\/strong><\/td>Chronic type\u202f2 inflammatory disease<\/td><\/tr>
Etiology<\/strong><\/td>Allergic hypersensitivity to fungi<\/td><\/tr>
Classification<\/strong><\/td>Specific subtype of chronic rhinosinusitis<\/td><\/tr>
Standard of Care<\/strong><\/td>Surgery + prolonged systemic steroids<\/td><\/tr>
Unmet Need<\/strong><\/td>High disease recurrence rate despite treatment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 LIBERTY\u2011AFRS\u2011AIMS Phase\u202f3<\/h2>\n\n\n\n
Endpoint<\/th>Dupixent<\/th>Placebo<\/th>Treatment Effect<\/th><\/tr><\/thead>
Sinus Opacification Improvement<\/strong><\/td>50%<\/strong><\/td>10%<\/td>+40\u202fpercentage points<\/strong><\/td><\/tr>
Assessment Timing<\/strong><\/td>Week\u202f52<\/td>Week\u202f52<\/td>Sustained benefit<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable<\/td>\u2013<\/td>Consistent with established Dupixent profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Dosing Regimen<\/h2>\n\n\n\n
Patient Population<\/th>Dose<\/th>Frequency<\/th><\/tr><\/thead>
Adults<\/strong><\/td>300\u202fmg<\/td>Every 2 weeks<\/td><\/tr>
Pediatrics \u2265\u202f60\u202fkg<\/strong><\/td>300\u202fmg<\/td>Every 2 weeks<\/td><\/tr>
Pediatrics 30\u201360\u202fkg<\/strong><\/td>200\u202fmg<\/td>Every 2 weeks<\/td><\/tr>
Pediatrics 15\u201330\u202fkg<\/strong><\/td>300\u202fmg<\/td>Every 4 weeks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Dupixent Mechanism & Franchise<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>Fully human monoclonal antibody<\/td><\/tr>
Target<\/strong><\/td>IL\u20114<\/strong> and IL\u201113<\/strong> signaling pathways<\/td><\/tr>
Mechanism<\/strong><\/td>Inhibition of type\u202f2 inflammatory responses<\/td><\/tr>
Approved Indications<\/strong><\/td>Sino\u2011nasal, skin, gut, and respiratory diseases driven by type\u202f2 inflammation<\/td><\/tr>
New Addition<\/strong><\/td>AFRS (10th+ indication for Dupixent franchise)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n